Long-term subcutaneous immunoglobulin use in inflammatory myopathies: A retrospective review of 19 cases

Autoimmunity Reviews

Volumn 15, Issue 3, 2016, Pages 281-286

  Cherin, Patrick ^a   Belizna, Cristina ^b   Cartry, Odile ^c   Lascu Dubos, Georgeta ^d   de Jaeger, Christophe ^e   Delain, Jean Christophe ^f   Crave, Jean Charles ^f   Hachulla, Eric ^g  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b ANGERS UNIVERSITY HOSPITAL   (France)

^c Clinique mutualiste catalane   (France)

^d Hopital Max Fourestier   (France)

^e Institut de Médecine et Physiologie de la Longévité   (France)

^f Octapharma   (France)

^g LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Dermatomyositis; Efficacy; Inclusion body myositis; Intravenous immunoglobulin (IVIg); Polymyositis; Safety; Subcutaneous immunoglobulin (SCIg)

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; IMMUNOGLOBULIN; METHOTREXATE;

ADULT; AGED; CASE STUDY; CHILL; CLINICAL ARTICLE; CLINICAL PRACTICE; CONNECTIVE TISSUE DISEASE; CORTICOSTEROID THERAPY; DERMATOMYOSITIS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; FEASIBILITY STUDY; FEMALE; FOLLOW UP; FRANCE; HEALTH STATUS; HOT FLUSH; HUMAN; IMMUNOTHERAPY; INCLUSION BODY MYOSITIS; LOCAL SKIN REACTION; LONG TERM CARE; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; MUSCLE STRENGTH; MYALGIA; MYOSITIS; PAIN; PATIENT COMPLIANCE; PATIENT SAFETY; POLYMYOSITIS; RETROSPECTIVE STUDY; REVIEW; YOUNG ADULT; IMMUNOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION;

HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFUSIONS, SUBCUTANEOUS; MUSCLE STRENGTH; MYOSITIS; RETROSPECTIVE STUDIES;

EID: 84958923680     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2015.12.003     Document Type: Review

References (30)

1. Cherin P., Herson S., Wechsler B., et al. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med 1991, 91:162-168.
2. Dalakas M.C., Illa I., Dambrosia J.M., et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993, 329:1993-2000.
3. Marie I., Hachulla E., Hatron P.Y., et al. Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis. J Rheumatol 2001, 28:2230-2237.
4. Marie I., Menard J.F., Hatron P.Y., et al. Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73 patients. Arthritis Care Res. 2010, 62:1748-1755.
5. Marie I., Hatron P.Y., Dominique S., et al. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum 2011, 63:3439-3447.
6. Cherin P., Herson S., Wechsler B., et al. Intravenous immunoglobulin for polymyositis and dermatomyositis. Lancet 1990, 336:116.
7. Cherin P., Piette J.C., Wechsler B., et al. Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients. J Rheumatol 1994, 21:1092-1097.
8. Elovaara I., Apostolski S., van Doorn P., et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol 2008, 15:893-908.
9. Dalakas M.C. Immunotherapy of myositis: issues, concerns and future prospects. Nat Rev Rheumatol 2010, 6:129-137.
10. Gurcan H.M., Keskin D.B., Ahmed A.R. Information for healthcare providers on general features of IGIV with emphasis on differences between commercially available products. Autoimmun Rev 2010, 9:553-559.
11. Chapel H.M., Spickett G.P., Ericson D., et al. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 2000, 20:94-100.
12. Gardulf A., Nicolay U., Asensio O., et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies-a prospective, multi-national study. J Clin Immunol 2006, 26:177-185.
13. Berger M. Subcutaneous administration of IgG. Immunol Allergy Clin North Am 2008, 28:779-802. viii.
14. Danieli M.G., Pettinari L., Moretti R., et al. Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application. Autoimmun Rev 2011, 10:144-149.
15. Cherin P., Delain J.C., de Jaeger C., Crave J.C. Subcutaneous immunoglobulin use in inclusion body myositis: a review of 6 cases. Case Rep Neurol 2015, 7:227-232.
16. Pars K., Garde N., Skripuletz T., et al. Subcutaneous immunoglobulin treatment of inclusion-body myositis stabilizes dysphagia. Muscle Nerve 2013, 48:838-839.
17. Misbah S., Sturzenegger M.H., Borte M., et al. Subcutaneous immunoglobulin: opportunities and outlook. Clin Exp Immunol 2009, 158(Suppl. 1):51-59.
18. Cherin P., Marie I., Michallet M., et al. Management of adverse events in the treatment of patients with immunoglobulin therapy: a review of evidence. Autoimmun Rev 2015.
19. Danieli M.G., Moretti R., Gambini S., et al. Open-label study on treatment with 20% subcutaneous IgG administration in polymyositis and dermatomyositis. Clin Rheumatol 2014, 33:531-536.
20. Cherin P., Pelletier S., Teixeira A., et al. Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum 2002, 46:467-474.
21. Hoogendijk J.E., Amato A.A., Lecky B.R., et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 2004, 14:337-345.
22. Fernandez-Cruz E., Kaveri S.V., Peter H.H., et al. 6th International immunoglobulin symposium: poster presentations. Clin Exp Immunol 2009, 158(Suppl. 1):60-67.
23. Misbah S.A., Baumann A., Fazio R., et al. A smooth transition protocol for patients with multifocal motor neuropathy going from intravenous to subcutaneous immunoglobulin therapy: an open-label proof-of-concept study. J Peripher Nerv Syst 2011, 16:92-97.
24. Cherin P., Pelletier S., Teixeira A., et al. Intravenous immunoglobulin for dysphagia of inclusion body myositis. Neurology 2002, 58:326.
25. Quinti I., Soresina A., Agostini C., et al. Prospective study on CVID patients with adverse reactions to intravenous or subcutaneous IgG administration. J Clin Immunol 2008, 28:263-267.
26. Danieli M.G., Gelardi C., Pedini V., et al. Subcutaneous IgG in immune-mediate diseases: proposed mechanisms of action and literature review. Autoimmun Rev 2014, 13:1182-1188.
27. Eftimov F., Vermeulen M., de Haan R.J., et al. Subcutaneous immunoglobulin therapy for multifocal motor neuropathy. J Peripher Nerv Syst 2009, 14:93-100.
28. Markvardsen L.H., Debost J.C., Harbo T., et al. Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 2013, 20:836-842.
29. Ochs H.D., Gupta S., Kiessling P., et al. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol 2006, 26:265-273.
30. Kittner J.M., Grimbacher B., Wulff W., et al. Patients' attitude to subcutaneous immunoglobulin substitution as home therapy. J Clin Immunol 2006, 26:400-405.